IQ EQ FUND MANAGEMENT IRELAND Ltd Purchases 5,929 Shares of Accolade, Inc. (NASDAQ:ACCD)

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in Accolade, Inc. (NASDAQ:ACCD) by 49.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,804 shares of the company’s stock after buying an additional 5,929 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Accolade were worth $61,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. EntryPoint Capital LLC boosted its position in shares of Accolade by 128.5% during the 4th quarter. EntryPoint Capital LLC now owns 83,787 shares of the company’s stock valued at $287,000 after acquiring an additional 47,113 shares in the last quarter. Intech Investment Management LLC lifted its stake in Accolade by 48.8% during the fourth quarter. Intech Investment Management LLC now owns 36,984 shares of the company’s stock worth $126,000 after purchasing an additional 12,124 shares during the period. Tocqueville Asset Management L.P. boosted its holdings in Accolade by 100.0% during the fourth quarter. Tocqueville Asset Management L.P. now owns 580,000 shares of the company’s stock valued at $1,984,000 after purchasing an additional 290,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Accolade by 84.1% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 634,470 shares of the company’s stock valued at $2,170,000 after purchasing an additional 289,747 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Accolade in the 4th quarter worth approximately $120,000. Institutional investors own 84.99% of the company’s stock.

Accolade Stock Down 0.1 %

Shares of ACCD opened at $6.99 on Friday. The firm has a market capitalization of $573.13 million, a price-to-earnings ratio of -3.11 and a beta of 2.18. Accolade, Inc. has a 52 week low of $3.08 and a 52 week high of $10.45. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63. The business’s fifty day moving average price is $6.94 and its two-hundred day moving average price is $4.95.

Accolade (NASDAQ:ACCD) last issued its quarterly earnings results on Friday, January 10th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. On average, analysts predict that Accolade, Inc. will post -1.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ACCD shares. William Blair cut Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Stephens reaffirmed an “equal weight” rating and issued a $7.03 target price on shares of Accolade in a report on Wednesday, February 12th. Needham & Company LLC reissued a “hold” rating on shares of Accolade in a report on Wednesday, January 8th. Raymond James reaffirmed a “market perform” rating on shares of Accolade in a research note on Thursday, January 9th. Finally, Canaccord Genuity Group reiterated a “hold” rating on shares of Accolade in a research note on Wednesday, January 8th. Thirteen investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $6.51.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.